Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Shun-ichi Wada"'
Autor:
Jiameng Sun, Yiming Zhang, Joshua A. Adams, Cassandra B. Higgins, Shannon C. Kelly, Hao Zhang, Kevin Y. Cho, Ulysses G. Johnson, Benjamin M. Swarts, Shun-Ichi Wada, Gary J. Patti, Leah P. Shriver, Brian N. Finck, Erik D. Herzog, Brian J. DeBosch
Publikováno v:
Cell Reports, Vol 43, Iss 10, Pp 114865- (2024)
Summary: Organisms integrate circadian and metabolic signals to optimize substrate selection to survive starvation, yet precisely how this occurs is unclear. Here, we show that hepatocyte Period 1 (Per1) is selectively induced during fasting, and mic
Externí odkaz:
https://doaj.org/article/f3f84b6930c6468d8267aafa1547506a
Publikováno v:
Chemical Communications. 56:12025-12028
From the perspective of the preparation of a DNA-based nanowire containing an array of metal ions, DNA-polymerase-catalyzed primer extension reactions were investigated and the formation of up to ten consecutive T-HgII-T base pairs was achieved by th
Publikováno v:
Chemistry & Biodiversity. 19
MAP(Aib)-cRGD, which is a conjugate of an α-aminoisobutyric acid (Aib)-containing amphipathic helical peptide [MAP(Aib)] with a α v b 3 integrin binding ligand, cRGD, at the C-terminus of the helical peptide, has been developed for siRNA delivery i
Autor:
Shun‐ichi Wada, Honami Arimura, Miho Nagayoshi, Ryuichi Sawa, Yumiko Kubota, Kazuaki Matoba, Chigusa Hayashi, Yuko Shibuya, Masaki Hatano, Yasuhiro Takehana, Shun‐ichi Ohba, Yoshihiko Kobayashi, Takumi Watanabe, Masakatsu Shibasaki, Masayuki Igarashi
Publikováno v:
Advanced Biology. 6:2101309
Nonreducing disaccharide trehalose is used as a stabilizer and humectant in various products and is a potential medicinal drug, showing curative effects on the animal models of various diseases. However, its use is limited as it is hydrolyzed by treh
Autor:
Tatsuya, Funai, Chizuko, Tagawa, Osamu, Nakagawa, Shun-Ichi, Wada, Akira, Ono, Hidehito, Urata
Publikováno v:
Chemical communications (Cambridge, England). 56(80)
From the perspective of the preparation of a DNA-based nanowire containing an array of metal ions, DNA-polymerase-catalyzed primer extension reactions were investigated and the formation of up to ten consecutive T-Hg
Autor:
Tomoyuki Kimura, Masayuki Igarashi, Kiyoko Iijima, Hideki Hashizume, Ryuichi Sawa, Shun-ichi Wada, Kazuma Yamashita
Publikováno v:
The Journal of Antibiotics. 71:129-134
In the course of optimizing pargamicin A production in Amycolatopsis sp. ML1-hF4, we discovered novel cyclic depsipeptide compounds in the broth and designated them valgamicins A, C, T and V. The structures of these molecules were determined by spect
Autor:
Shun-ichi Wada, Masaki Hatano, Manabu Kawada, Chigusa Hayashi, Yuko Shibuya, Yumiko Kubota, Fumiki Iwanami, Ryuichi Sawa, Kiyoko Iijima, Miho Nagayoshi, Masayuki Igarashi
Publikováno v:
The Journal of Antibiotics. 70:1078-1082
Two new 4’-acetylated analogs of chrysomycin were discovered during the screening for antitumor agents from the metabolites of actinomycetes. Their structures and physicochemical properties were determined by standard spectrometric analyses. Their
Publikováno v:
The Journal of Antibiotics. 71:39-44
Thanks to the pioneering work done by Professor Hamao Umezawa, bioactive compounds have been used in treatment of several diseases including cancer. In this review, we discuss our work, which focuses on developing new candidates for anti-tumor drugs
Autor:
Teruyuki Tahara, Mitsuaki Yamashita, Hironobu Matsumoto, Shun-ichi Wada, Kiyoshi Tomioka, Akira Iida, Shinya Hayakawa
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:4133-4144
We developed novel nucleoside-based topoisomerase II selective inhibitors and showed that small structural units, such as catechols, are essential for DNA topoisomerase II inhibitory activity. Moreover, nucleoside analogues containing TBS and 1,3-dit
Autor:
Kazuhisa Uchiyama, Yukihiro Akao, Junsuke Hayashi, Sang-Woong Lee, Yosuke Inomata, Hidehito Urata, Shun-ichi Wada, Kazumasa Komura, Yuko Ito, Tomohito Tanaka, Kohei Taniguchi
Publikováno v:
Molecular pharmaceutics. 16(11)
Replacement therapy with tumor suppressive microRNA (TS-miRNA) might be the next-generation oligonucleotide therapy; however, a novel drug delivery system (DDS) is required. Recently, we developed the cell-penetrating peptide, model amphipathic pepti